ArticleFrontiers in microbiology2025
Inactivated vaccines derived from bovine viral diarrhea virus B3 strain elicit robust and specific humoral and cellular immune responses.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Cross-protective immunity elicited by heterologous DNA prime/subunit or adenovirus boost regimens against bovine viral diarrhea virus.BMC veterinary research · 2026Article
- Bovine Viral Diarrhea Virus and Vaccine Protection Strategies.Veterinary sciences · 2026Review
- A Novel Bicistronic Adenovirus Vaccine Elicits Superior and Comprehensive Protection Against BVDV.Microorganisms · 2026Article
- Case Report: Integrated imaging and molecular diagnostic approach to congenital hip dysplasia in a Hanwoo calf.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bovine viral diarrhea-mucosal disease (BVD-MD) is a significant viral disease in cattle caused by infection with bovine viral diarrhea virus (BVDV). Xinjiang, a major pastoral region in China, is heavily affected by this disease. Owing to the high genetic variability of BVDV, developing cross-protection vaccines targeting predominant strains is essential. Methods: In this study, inactivated vaccines were developed using BVDV strains isolated from Xinjiang, including BVDV-1 (B1), BVDV-2 (B2), XJ-BVDV-3 (B3), and BVDV-LC (LC). BALB/c mice were immunized, and immune responses were assessed via ELISpot, ELISA, and virus neutralization assays. On day 42 post-immunization, the mice were challenged with BVDV, and the viral loads were quantified. Results: The vaccines showed stable characteristics and sterility and are suitable for immunization studies. All the vaccines stimulated interferon-gamma (IFN-γ) production, and the IFN-γ levels in the B1 and B3 groups were significantly higher than those in the commercial vaccine group ( Discussion: In conclusion, this study developed inactivated vaccines from the B1, B2, B3, and LC strains, all of which induce robust immune responses. Among these, the B3 inactivated vaccine show great potential for commercialization, providing a valuable reference for BVDV prevention and control in Xinjiang.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.